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I. Obesity: an epidemic health and economic burden  
___________________________________________________________________________ 
Within the last three decades obesity has become an ever more important global issue with 
far-reaching social and economic impact. Obesity significantly increases the risk of metabolic 
and vascular diseases such as type 2 diabetes, fatty liver disease, hypertension, coronary heart 
disease and peripheral artery disease and reduces life expectancy (Kitahara et al., 2014) . 
Therefore, there exists a pressing need for a deeper understanding of obesity and its therapy in 
order to develop novel strategies in the fight against this threat. 
For a long time obesity was disregarded as a „nice-to-have-problem“, especially in the light of 
the massive underfeeding issues in third-world-countries. This attitude may have contributed 
to an alarming development: in the last decades obesity has risen to a true „epidemic“. 
Worldwide prevalence has more than doubled since 1980 and nowadays more people die from 
the consequences of obesity than of underweight (WHO, 2014). In Germany, the Robert-
Koch-Institut found an obesity prevalence of 23,3% in men and 23,9% in women in 2011 
(Kurth, 2012). As obesity is related to age (Max-Rubner-Institut, 2008), an ever more aging 
population might further boost numbers in the coming years in Germany. 
The WHO defines obesity as an accumulation of body fat that exceeds the normal range, 
likely causing negative consequences on health. Obesity can be objectified using the surrogate 
marker body mass index (BMI) that is defined by body-weight in kilograms divided by the 
square of height in meters (kg/m2). A BMI greater than or equal to 30 is generally considered 
as obesity, whereas the range between 25 and 30 is termed overweight (WHO, 2014). A 
shortcoming of using BMI is that it neither covers constitutional differences in physique, nor 
the distribution-pattern of body fat. It has been shown that visceral fat mass rather than the 
absolute amount of body fat determines cardiovascular risk (Després, Lemieux & Prud, 
2001). Taking these findings into account, the concept of „abdominal obesity“ has been 
established, being defined by a waist circumference of greater than 88 cm in women and 
greater than 102 cm in men (EASO, 2002).  
Obesity is associated with a great variety of pathologies in nearly all organs. Most striking, 
however, are its negative effects on the cardiovascular and metabolic system. Major 
cardiovascular risk factors are clustered in the concept of the metabolic syndrome, presenting 
different metabolic dysfunctions with complex and interdependent pathophysiological 
relationships. The International Diabetes Foundation (IDF) published updated criteria for the 
metabolic syndrome in 2005. In contrast to former definitions, it necessarily requires the 
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presence of obesity. In addition any two of the following criteria must be met: raised 
triglycerides, reduced HDL cholesterol, raised blood pressure or raised fasting plasma glucose 
(Zimmet, Magliano, Matsuzawa, Alberti & Shaw, 2005). 
Each of these factors has a high correlation with obesity. In particular, the discovery of a 
whole range of adipokines, hormones secreted by adipose tissue, has provided new insight 
into the tight relationship of obesity and metabolic dyshomeostasis. Dysregulation of 
adipokines has been shown to have strong negative impact on different metabolic systems, 
e.g. on insulin resistance (Rabe, Lehrke, Parhofer & Broedl, 2008), atherosclerosis (Lau, 
Dhillon, Yan, Szmitko & Verma, 2005) and dyslipidaemia (Sato et al., 2005), thus represent-
ing a major link between obesity and other determinants of the metabolic syndrome.  
The destructive effects of obesity are not limited to the cardiovascular system. Although un-
derlying mechanisms remain largely obscure, it seems to be a major risk factor for different 
types of cancer. Calle, Rodriguez, Walker-Thurmond & Thun conducted a prospective study 
in the U.S. (2003), showing significantly increased death rates among obese patients due to 
cancers of the esophagus, colon and rectum, liver, gallbladder, pancreas, and kidney. The 
American Cancer Society (2015) estimated that 20% of all cancer-related deaths can be traced 
back to obesity. Other medical conditions associated with obesity are musculoskeletal disor-
ders like arthritis (Wearing, Hennig, Byrne, Steele & Hills, 2006), infertility (Norman & 
Clark, 1998), deterioration of pulmonary function (Zerah et al. 1993), fatty liver (Fabbrini, 
Sullivan & Klein, 2010) and depression (Dong, Sanchez & Price, 2004).  
Due to its multiple direct and indirect negative effects on the health care system and on pro-
ductivity, it is difficult to measure the economic implications of this new epidemic. Total costs 
of overweight and obesity have been estimated to add up to 16.8 billion Euro in Germany in 
2008 (Lehnert, Streltchenia, Konnopka, Riedel-Heller & König, 2015). It seems plausible that 
these numbers have risen in the meantime and will continue to do so.  
II. Dysregulation of energy homeostasis: key driver for obesity and 
post-diet weight regain  
___________________________________________________________________________ 
Despite intensive research on the subject, most pathomechanisms leading to obesity are not 
fully understood. It is generally accepted that the derangement of systems that ensure energy-
homeostasis is responsible for its development. When energy intake exceeds energy expendi-
ture, an energy surplus develops that is stored by the body in anabolic processes. If the surplus 
 3
is sustained over a long time, it results in increased body fat and body weight. The changes in 
our environment with an evermore growing food supply have massively driven this imbal-
ance. Worldwide per capita food consumption has risen by about 20% since 1964, amounting 
to 2803 kcal in global average and even as much as 3380 kcal (1964: 2947 kcal) in industrial 
countries in 1997 (Bruinsma, 2003). In addition, technological progress has encouraged a 
sedentary lifestyle. The WHO estimates that 80% of the adult population needs more physical 
exercise (2015).  
Information about nutrient status and energy stores is delivered by different hormonal, meta-
bolic and neural signals that are integrated in CNS-circuits mainly located in the hy-
pothalamus. Depending on this input, metabolic and behavioral parameters are adjusted in 
order to guarantee the maintenance of a stable body weight. As far back as 1953, Kennedy 
proposed that the body strives to keep body weight within a certain target range Deviations 
from this baseline, for example caused by a period of fasting, are actively opposed by central 
compensatory mechanisms - in this case increased food intake and reduced energy expendi-
ture.  
In the face of the described changes in the environment, however, these mechanisms obvious-
ly fail in limiting weight gain. In the sixties, the „thrifty genes hypothesis“ (Neel, 1999) ex-
pressed for the first time the idea that human physiology and genetics - geared towards effi-
cient utilization and storage of food - are not sufficiently adapted to increasing food supply 
and sedentary lifestyle. The fact that caloric restriction leads to compensatory homeostatic 
adaptations not only in lean, but also in obese individuals suggests that there is a shift in target 
weight in these patients. Thus instead of a lack of regulation, a raised set-point may be re-
sponsible for the poor long-term effects of diet-induced weight loss (Morton & Schwartz, 
2006; Ryan, Woods & Seeley, 2012). 
Significant progress has been made in understanding some of the mechanisms forming the 
highly complex regulation of feeding behavior and energy homeostasis. The adipokine leptin 
was discovered as a crucial constituent of an adipose-tissue-brain-axis regulating energy ho-
meostasis, after initial proposal from hypothalamic lesioning and parabiosis experiments per-
formed on animals by Hetherington & Ranson (1940) and Coleman (1978), respectively. Lep-
tin is the product of the ‚obese’ (ob) gene (Zhang et al., 1994) and its plasma and cerebrospi-
nal fluid levels correlate with the body mass index (Schwartz, Peskind, Raskind, Boyko & 
Porte, 1996) thereby signaling the amount of body fat to the brain. It was shown that obesity 
as a result of a leptin deficient genotype can be reversed by the administration of leptin 
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(Friedman & Halaas, 1998) and that mutation in the human leptin receptor gene results in ear-
ly-onset obesity (Clément et al., 1998). Thus, leptin is part of a negative feedback loop regula-
ting body weight.  
The leptin signal seems to be processed mainly by the arcuate nucleus (see figure 1) that is 
situated in the tuberal region of the hypothalamus and is equipped with leptin receptors (Cone 
et al., 2001). Its anatomical proximity to areas with a high permeability of the blood-brain-
barrier makes it an ideal hub for the integration of other peripheral such as gastrointestinal 
hormones like the orexigenic ghrelin (Cone et al., 2001). The regulatory effectors of this loop 
are presented by different neuropeptides 
that are secreted by the nucleus and lead 
to an adjustment of food intake: Neuro-
peptide Y (NPY) is a hypothalamic pep-
tide that was shown to increase feeding 
(Clark, Kalra, Crowley & Kalra, 1984) 
and to promote changes associated with 
the metabolic syndrome (Zarjevski et 
al., 1993). Agouti-related protein (Agrp) 
is co-expressed with NPY in the arcuate 
nucleus (Hahn, Breininger, Baskin & 
Schwartz, 1998) and increases food in-
take by antagonizing the anorexigenic peptide alpha-MSH at the level of the melanocortin 4 
receptor (Rossi et al., 1998). Alpha-MSH itself is derived from the precursor protein pro-
opiomelanocortin (POMC) in the arcuate nucleus (Emeson & Eipper, 1986) being adjacent to 
AgRP/NPY neurons (Hahn et al., 1998), and decreases food intake by binding to melanocor-
tin receptors (Fan et al., 1997). It was shown that the orexigenic neuropeptides NPY and 
AgRP are inhibited by leptin, whereas the secretion of the anorexigenic POMC is stimulated 
(Elias et al., 1999; Schwartz et al., 2000), resulting in decreased food intake. However, this 
regulation process is deranged in diet induced obesity by a decreased leptin sensitivity in the 
arcuate nucleus (Münzberg, Flier & Bjørbæk,, 2004), indicating a central role for this mecha-
nism in the development of obesity. 
Besides the behavioral response that regulates energy intake via satiety or appetite sensation, 
energy homeostasis can be influenced by adjusting the dissipation of energy in the form of 
heat. This direct effect on basal metabolism and, correspondingly, energy expenditure, has 
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Figure 1: central effects of leptin in the arcuate nucleus 
(adapted from Varela & Horvath, 2012)  
gained new importance in recent years in obesity research. Importantly, it was shown that 
deviations from the usual weight, including long-term overweight, cause an adaptation in 
energy expenditure. In accordance with the set-point principle, an elevation of body weight 
leads to an increase in energy expenditure whereas weight loss causes a compensatory 
decrease (Leibel, Rosenbaum & Hirsch, 1995). This metabolic adaptation can be detected 
beyond the initial phase of pronounced weight loss and may therefore be a crucial contributor 
to obesity recurrence (Rosenbaum, Hirsch, Gallagher & Leibel, 2008).  
The administration of leptin in ob/ob mice was shown to produce weight loss not only by re-
ducing food intake, but also by increasing energy expenditure (Levin, Nelson, Gurney, Van-
dlen & de Sauvage, 1996). This effect is likely to be a consequence of elevated thermogenetic 
activity in adipose tissue (Scarpace, Matheny, Pollock, Tümer, 1997). Thus, leptin resistance 
may maintain overweight and obesity not only via increasing food intake, but also by reduc-
ing thermogenesis and energy expenditure.  
Together these results support the idea of a shift in the bodyweight set-point that is in part 
mediated by altered basal metabolism, and may contribute to the poor long-term outcome of 
diet-induced weight loss in obese patients. 
III. Brown and beige adipose tissue and their effect on energy and meta-
bolic control 
___________________________________________________________________________ 
For a long time it was thought that the ability to generate heat via brown adipose tissue (BAT) 
is reserved to newborn humans and small mammals. The proportion of body surface to mass 
predisposes them to hypothermia, making brown fat a crucial survival tool. However, a rela-
tively recent and unexpected discovery was made in retrospective analyses of humans using 
FDG-PET imaging data: significant amounts of metabolically active tissue were found in se-
veral body regions of human adults, most prominently in the supraclavicular region (Cohade, 
Osman, Pannu & Wahl, 2003; Nedergaard, Bengtsson & Cannon, 2007). This was subse-
quently confirmed at the histological level (Virtanen et al., 2009; van Marken Lichtenbelt et 
al., 2010) and has sparked new interest in the topic as the biochemical properties of brown fat 
provide different approaches for the treatment of obesity and associated metabolic disorders.  
The functionality of brown fat is based on the reciprocal relation of energy efficiency and 
thermogenesis that follows from the first law of thermodynamics. Hence, in order to generate 
heat, the efficiency of a metabolic process has to be decreased. This is accomplished in brown 
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adipocytes via a transporter called uncoupling protein 1 (UCP-1) located in the inner mito-
chondrial membrane (see figure 2). In all body cells, the electron transport chain transfers pro-
tons across the inner mitochondrial membrane in order to create an electrochemical gradient. 
In ordinary cells, this gradient is used to synthesize adenosine triphosphate (ATP). UCP-1 
short circuits this process. It allows protons to cross the inner membrane of mitochondria, and 
in doing so, undermining the work of the respiratory chain. As a consequence, the electro-
chemical gradient is uncoupled from 
ATP-synthesis and the efficiency of the 
system is reduced close to zero. This 
results in the release of oxidation ener-
gy in the form of heat. The oxidation of 
fatty acids serves as an energy supplier 
for this process, thus energy expenditu-
re of the tissue is increased (Ricquier, 
2011). In addition to their expression of UCP1, brown fat cells differ in several histological 
features from white adipose tissue. They contain not only one big lipid droplet, but several 
small lipid droplets, and carry a higher number of mitochondria. Furthermore, they are locali-
zed in certain anatomic areas, for example in the interscapular region of infants.  
During recent years a new lineage of cells in white fat depots has been characterized that 
share similar histological properties with brown fat cells, but have a different ontogenetic 
background. While ordinary brown adipocytes stem from a line of cells that express myogenic 
factor 5 (myf5) and resemble muscle cells, this new type of cell is derived form myf5-nega-
tive precursors (Seale et al,. 2008). It is now clear that these cells arise from a smooth muscle 
origin that express the marker smooth muscle actin (Long et al., 2014). Interestingly, these 
cells seem to account for a large proportion of the thermogenic active tissue in adult humans 
that was discovered in PET-scans (Wu et al., 2012). Furthermore, these cells have been found 
to be disseminated all over white adipose tissue (with highest concentrations in inguinal fat in 
rodents), hence presenting a hybrid form of brown and white fat cells. On account of their in-
termediate character they were called „beige“ cells. 
In contrast to classical brown and white fat cells, beige cells are able to flexibly adapt their 
biochemical profile to the current metabolic and climatic state (Harms & Seale, 2013). While 
in a basal state they only express very low levels of UCP1, various stimuli are able to trigger a 
transformation to a thermogenically active state. This condition is characterized by high 
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Figure 2: functionality of UCP-1 as a transmembrane pro-
teine (adapted from Harms & Seale, 2013)  
UCP1-expression and multilocular lipid droplets, thereby rendering the cells similar to 
classical brown fat cells. Different mechanisms have been shown to contribute to this 
transformation. However, cold exposure seems to have the highest physiological relevance. 
This effect is mediated mainly by the sympathetic nervous system via noradrenaline that 
activates beta-3 adrenoceptors (Vitali et al., 2012). Aging was described to block the ability of 
white adipocytes to transform to beige cells. This process could be reversed by inhibiting 
senescence pathways, which could extend the therapeutic potential of beige-cell activation to 
older obese individuals (Berry et al., 2016).  
Aside from its thermoregulatory function, UCP1-positive tissues are of great importance to 
the regulation of body weight as well as to other metabolic parameters such as blood sugar 
and lipid levels (Kajimura, Spiegelman & Seale, 2015). These effects make it an extremely 
attractive target of therapy concepts for obesity, diabetes and other metabolic disorders. 
UCP1-deficiency achieved by genetic ablation was shown to cause obesity in mice when they 
were kept under thermoneutral conditions (Feldmann, Golozoubova, Cannon & Nedergaard, 
2009). In addition, these mice showed no diet-induced thermogenesis that physiologically 
counteracts weight gain in wild-type mice, which resulted in greater weight-gain on a high-fat 
diet (Feldmann et al., 2009). Recently Claussnitzer et al provided additional evidence for the 
importance of altered thermogenesis in the pathogenesis of obesity in humans (2015). They 
showed that variants of the FTO allele that present some of the strongest genetic associations 
with obesity inhibit the development of beige adipocytes and thus decreases energy-expendi-
ture. Complementary to these findings, it was shown that the expansion of beige fat achieved 
by a genetical inactivation of inositol hexakisphosphate kinase (IP6K) reduced diet-induced 
weight gain and had beneficial metabolic effects in mice (Zhu et al., 2016). Together these 
results highlight the role of brown and beige fat in the regulation of body weight.  
However what might be of even greater importance is the positive impact on metabolism 
associated with increased activity of brown and beige cells. Recent studies have delivered 
substantial evidence for a significant role of brown and beige adipose tissue in the 
improvement of glucose homeostasis. These mechanisms seem to work independently of 
weight-loss-effects. Transplantation of brown adipose tissue to mice was shown to enhance 
insulin sensitivity, which could be observed even before weight-loss. The effect seemed to be 
fully attributable to increased glucose uptake into the transplanted tissue (Standford et al., 
2013). Comparable observations regarding glucose homeostasis were made when human 
beige adipose tissue was implanted into mice (Min et al., 2016). 
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In addition to its role in glucose homeostasis, brown adipose tissue serves as a consumer of 
triglycerides and thereby actively reduces plasma lipid levels. Cold exposure of mice 
increases expression of lipoprotein lipase in brown fat which stimulates the metabolization of 
triglycerides, respectively lowers triglyceride plasma levels (Bartelt et al., 2011).  
In summary brown and beige fat provide valuable tools for the fight against obesity and 
cardiovascular risk factors: Not only do they actively support weight loss but they also seem 
to work as a „sink“ that drains metabolites like glucose and triglycerides (Hankir, Cowley & 
Fenske, 2016). Therefore they might serve as therapeutic targets for metabolic disorders like 
diabetes mellitus or hyperlipidemia  - independently of their effect on body weight.  
IV. Bariatric surgery as an anti-obesity therapy concept  
___________________________________________________________________________ 
Studies investigating the long-term benefits of conservative weight-loss strategies show that 
the so called Yo-Yo-effect foils sustained therapy success in the majority of patients. Only 
about one third of patients are able to maintain a weight-loss of 10% after 5 years (Anderson, 
Konz, Frederich & Lutz, 2001).  
To date Roux-en-Y gastric-bypass (RYGB) is the most 
widely performed surgical intervention in weight-loss 
therapy. In contrast to conservative methods like lifestyle 
modification, it not only provides substantial and 
sustained weight-loss, but it is also proven to reduce 
mortality rates (Arterburn et al., 2015). Ten years after 
surgery, patients have maintained an average weight loss 
of 25% compared to their initial body weight (Sjostrom 
et al., 2007). Furthermore, patients show a general 
decrease of cardiovascular risk factors like hypertension 
and plasma triglycerides and tend to be less sedentary 
(Sjöström et al., 2007). In the therapy and prevention of 
type 2 diabetes, metabolic surgeries like RYGB are the 
most effective modality (Booth et al., 2014; Schauer et al., 2014; Mingrone et al., 2012). 
Remarkably, its effect on glucose tolerance seems to be mediated at least in part 
independently of weight loss (Laferrere et al., 2008). RYGB has also been shown to 
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Figure 3: basic principle of RYGB 
(adapted from „Roux-en-Y Gastric 
Bypass“, 2017) 
significantly decrease incidence and mortality of several cancers that are likely to be caused 
by obesity (Adams et al., 2009).  
Guidelines recommend obesity surgery for patients with BMI of over 40 kg/m2 (Berg et al., 
2014). Depending on the presence of secondary diseases, especially diabetes, this 
recommendation is extended to patients with a BMI of 30-40 kg/m2 (Berg et al., 2014).  
The basic principle of the RYGB-surgery (see figure 3) is the creation of a small gastric pouch 
that is divided from the rest of the stomach. It usually has a small volume of around 30 milli-
liters thereby allegedly restricting food-uptake. To connect this pouch to the rest of the intes-
tine, the jejunum is divided about 0.5 meters distal to the ligament of Treitz, and an end-to-
side gastrojejunostomy is performed. In a final step, a side-to-side jejunojejunostomy links the 
alimentary limb with the bilopancreatic limb. Here the digestive juices coming from the 
bilopancreatic limb have contact with food for the first time (Rubino et al., 2004).  
The underlying mechanisms of RYGB are still poorly understood. However recent research 
indicates that they reach far beyond caloric restriction and malabsorption caused by the 
anatomical modification of the intestine (see figure 4). In fact, several studies even suggest 
that the contribution of restriction (Bueter et al., 2010) and malabsorption (Carswell et al., 
2014) are of minor significance for weight-loss effects.  
The investigation of alternative mechanisms of RYGB has the potential to contribute signifi-
cantly to our understanding of the mutual relationships between the gastrointestinal tract and 
other regulatory metabolic systems. Importantly, RYGB has been shown to contribute to a 
recovery of the hypothalamic regulation of food intake that is deranged in diet induced obesi-
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Figure 4: potential contributing factors to weight loss after RYGB (adapted from Ashrafian et al., 2011) 
ty as described above. After surgery, elevated plasma levels of the gut hormones GLP-1 and 
PYY have been described (Le Roux et al., 2006). When applied intravenously in combination, 
these hormones show a synergistic inhibition of food intake (Neary et al., 2005). In line with 
this, the extent of weight loss is predicted by plasma levels of these hormones (Le Roux et al., 
2007; Fenske et al., 2012). Both hormones are likely to mediate their effect through modulati-
on of hypothalamic signaling (Challis et al., 2003; Turton et al., 1996). Furthermore, there is 
evidence for a suppression of the gastrointestinal hormone ghrelin after RYGB (Roth et al., 
2009), that acts as an orexigen by inducing the hypothalamic expression of AGRP and NPY 
(Seoane et al., 2003). In summary, the anatomical and physiological changes after RYGB 
seem to promote anorexigenic and suppress orexigenic pathways in the CNS, thereby actively 
reducing food intake.  
However food preference seems to be modulated not only in regard to quantity, but also 
quality of intake. After surgery, humans show reduced preference for high-fat diet when 
compared to patients after gastric banding (Le Roux et al., 2011). In accordance with this, rats 
were shown to prefer low-fat- over high-fat-chow after RYGB (Le Roux et al., 2011). These 
changes may be traced back to a decrease of the reward value of especially high-calorie food 
after RYGB in the sense of a diminished central hedonic response (Scholtz et al., 2014).  
Furthermore recent research has provided evidence that RYGB induces significant changes in 
the gut microflora that contribute to weight loss after surgery (Liou et al., 2013).  
The mechanisms of weight-loss induction and maintenance described so far mainly mediate 
their effect via a decrease of energy intake. As explained above, diet-induced weight loss has 
been shown to entail a compensatory decrease of energy expenditure that might be 
responsible for post-diet weight regain. However a range of studies have made a remarkable 
observation: RYGB not only prevents this effect, but actually increases energy expenditure. 
Werling et al. compared female patients having received either RYGB or gastric-banding and 
having lost similar amounts of weight 9 years after surgery. RYGB was found to be associated 
with a significant increase in postprandial energy expenditure (2013). Several studies 
provided data in support of this finding: Rats who underwent RYGB showed increased total 
energy expenditure that was not caused by locomotive activity (Bueter et al., 2010). 
Consistent with this, a body-weight-matched control group had to eat 40% less in order to 
reach the same weight-loss (Bueter et al., 2010). Carrasco et al. (2007) and Stylopoulos, 
Hoppin & Kaplan (2009) measured resting energy expenditure after RYGB in humans and 
rats respectively, with corresponding results.  
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When taken together, it becomes clear that RYGB induces weight loss not only via profound 
changes in the regulation of energy intake, but also by actively increasing the metabolism of 
energy. The mechanisms behind these effects are highly complex and need further elucidation.  
V. Objective of this work 
___________________________________________________________________________ 
As described above, alterations in the regulation of energy expenditure are likely to play a 
central role in the pathogenesis of obesity and may also contribute decisively to post-diet 
weight regain. Therefore, therapeutic strategies targeting the enhancement of energy expendi-
ture bear great potential in the fight against obesity. It was shown that thermogenesis after 
RYGB is increased when compared to a body-weight-matched control group. This might ex-
plain the surgery’s effect on energy expenditure (Bueter et al., 2010; Wilms, Ernst, Schmid, 
Thurnheer & Schultes, 2013). RYGB is the most widely performed obesity surgery. It pro-
duces a substantial and sustained weight-loss. Gaining deeper insight into its functionality 
may enable us to develop less invasive therapy strategies that mimic the effects of surgery. 
Various data suggest a central role for an increase of energy expenditure in the long-term suc-
cess of RYGB. But it remains unclear how this effect is achieved. 
To find out more about underlying mechanisms of increased energy expenditure after RYGB, 
we examined whether there is an enhanced recruitment of thermogenically active brown or 
beige adipose tissue. Apart from their energy consumption, these tissues have several 
beneficial effects on metabolism and therefore might contribute to the restoration of metabolic 
imbalances after RYGB.  
Due to the complexity of the biochemical changes induced by RYGB, there are several 
potential mechanisms that may lead to the observed increase of energy expenditure. However 
GLP-1 and bile acids, whose plasma levels are elevated after RYGB, have been reported to 
induce browning of adipose tissue (Osaka, Endo, Yamakawa & Inoue, 2005; Fang et al., 
2015). Furthermore - as described above - RYGB is probable to indirectly unfold its effect via 
hypothalamic regions like the arcuate and the paraventricular nucleus. These are strongly 
involved in the regulation of energy expenditure (Billington, Briggs, Harker, Grace & Levine, 
1994) and control the activation of thermogenically active tissue (Cao et al., 2011). We 
therefore hypothesized that potential browning of adipose tissue might be mediated by CNS-
stimulation, possibly caused by the profoundly altered hormonal and metabolic status after 
RYGB (see also figure 4).  
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VI. Publication 
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1. Introduction
The incidence of obesity and related comorbidities continues to
rise and represents one of modern civilization’s major health
and economic burdens [1,2]. Currently available anti-obesity
strategies are of limited long-term efficacy apart from surgical
procedures, which cause significant and sustained weight
loss in a majority of patients [3]. Further understanding the
mechanisms of weight loss maintenance underlying bariatric
surgery may therefore provide important insight and aid in the
development of novel less invasive obesity treatments.
In simple terms, obesity develops when energy intake
chronically exceeds expenditure. Therapeutic strategies for
obesity have mainly targeted caloric restriction through appetite
suppression and inhibition of fat absorption [4]. Compared to
those acting on central appetite regulation, therapies acting
peripherally may prove more beneficial, while causing fewer
harmful side effects [5]. Moreover, even minor weight loss
through caloric restriction is often redressed through complex
counter-regulatory mechanisms to maintain ‘isoenergetic’ con-
ditions [6,7]. The concept ofmanipulating peripheralmechanisms
to convert excess energy into heat through recruitment of brown
adipose tissue (BAT) [8,9] has therefore taken center stage for
novel anti-obesity drug development within recent years.
The emergence of brown adipocyte-like cells interspersed in
subcutaneous white adipose tissue (WAT) of subjects following
chronic exposure to cold (in a process referred to as ‘browning’)
is a physiological adaptation that maintains core body temper-
ature [10]. These cells comprise beige (also referred to as
inducible brown, brown-in-white, or brite) adipose tissue
(BeAT) which is currently the subject of intensive study due to
its energy expending and weight lowering capacity similar to
BAT [8]. Despite being functionally similar, BeAT is anatomi-
cally, morphologically, and developmentally distinct from BAT
[9] and can be identified by its unique gene expression profile
(e.g. Ear2, TMEM26) as well as high expression of thermoregu-
latory genes (e.g. UCP1, PRDM16, CIDEA) also found in BAT [11].
In adult man, BAT was originally described in the neck,
supraclavicular and other regions [12–14]. Moreover, chronic
cold exposure has been shown to result in stimulation and
expansion of supraclavicular BAT associated with increased
energy expenditure and decreased adiposity [15] attesting that
BAT is a promising target to treat human obesity [16]. Various
lines of evidence also support a prominent role for BeAT in
regulating whole body energy homeostasis. For instance, the
weight lowering effect of chronic β3 adrenoceptor agonist
treatment correlates with the levels of visceral WAT browning
in mice [17]. Interestingly, the myokine irisin, which protects
against diet-induced weight gain by increasing energy expen-
diture, causes the emergence of BeAT in subcutaneous WAT
[18,19], but has no effect on BAT thermogenic function [11,19].
These observations suggest that recruitment of BeAT may be
sufficient to lead to a state of maintained negative energy
balance. Also, in several clinical conditions associated with
weight loss, such as cancer-induced cachexia [20], and
phaeochromocytoma [21], browning of WAT in both subcuta-
neous and visceral depots has been demonstrated.
Although previous studies on weight loss mechanisms of
Roux-en-Y gastric bypass (RYGB) surgery have predominantly
focused on surgery-related changes in feeding behavior [22],
accumulating evidence from animal and human data suggest
that increased energy expenditure is another important under-
lying contributor of post-RYGB weight reduction [23–28]. The
mechanisms, however, for increased energy expenditure after
RYGB are poorly understood. In a previous study evaluating
BAT function in RYGB-operated rats, we did not find any
changes in UCP1 expression level or in vivo glucose uptake in
BAT compared to sham-operated ad libitum fed controls [29].
However, no comparisons were made to animals matched for
body weight. The potential role of WAT browning in adiposity
reduction after bariatric surgery has not been addressed so
far. Our objectives in this study, therefore, were to (1) assess
BAT thermogenic gene expression in diet-induced versus
RYGB surgery-induced weight loss maintenance and to (2)
determine whether emergence of BeAT in various WAT
depots occurs after RYGB.
2. Methods
2.1. Animals
Twenty four adult male Wistar rats (Janvier, Le Genest Saint
Isle, France) initially weighing ~250 g were housed individually
in wire-mesh cages at a constant temperature of 22–24 °C with
a 12-h light–dark cycle (lights on 7 a.m., off at 7 p.m.). Food and
water were provided ad libitum unless otherwise indicated. To
render them obese, rats were fed a high fat diet (HFD)
containing 51% kcal fat (EF-Rat D12451, Ssniff, Soest, Germany).
When body weights exceeded the obese target body weight of
500 g, rats were randomized either to RYGB (n = 10), or sham
operations (n = 14). Postoperatively, all animals were given a
diet of normal chowpowdermixedwithwater (wet diet) for one
day. Thereafter, animals were offered standard normal chow
(RM1 diet; Ssniff, DE-59494, Germany) ad libitum to avoid the
development of conditioned fat taste aversion and tomimic the
nutritional reality in patients after surgery. Following a 7-day
recovery period, sham-operated animals were allocated into
two groups: sham-operated animals with no dietary manipu-
lation (ad libitum fed shams [Sham], n = 7) and food restricted
shams, who received as much food daily as was necessary to
maintain a similar body weight to the RYGB rats (body weight-
matched shams [BWM], n = 7). From postoperative week 2,
body weight was measured weekly. From postoperative weeks
8 to 16 food intake was measured daily. All protocols were
approved by the Institutional Animal Care and Use Committee
at the University of Leipzig and with permission of the local
government of Saxony.
2.2. Surgical Procedures
Surgical procedures were performed by the same surgeon
(F.S.) according to an established protocol as previously
described [30]. This model of RYGB has been shown to result
in weight loss independent of malabsorption and to increased
resting energy expenditure and diet induced thermogenesis
[27]. Briefly, following a 6-hour food restriction period,
animals were anesthetized with 5% isoflurane and 2% oxygen.
Animals were then placed in a supine position on a heating
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pad and positioned in a nose cone tomaintain anesthesia (2–3%
isoflurane in oxygen 0.5 L/min) throughout surgery. The
abdominal wall was opened through a midline incision. For
the RYGB procedure, the jejunum was transected 16 cm aboral
to thepylorus of the stomach creating a proximal anddistal end
of the small bowel. The proximal end, being still continuous to
the remaining portion of the stomach, was anastomosed to the
ileum approximately 25 cm oral from the cecum, creating the
common channel. The stomach was then transected 3 mm
aboral to the gastroesophageal junction, creating a gastric
pouch of a size of no more than 2–3% of the original stomach
size at the proximal end and a gastric remnant at the distal end
of the transection respectively. The gastric remnant was closed
creating the biliopancreatic limb. Thereafter the distal end of
the small bowel was anastomosed in an end-to-side fashion to
the gastric pouch leading to formation of the alimentary limb. A
single RYGB procedure lasted approximately 70 minutes. For
sham operations, the small bowel and the gastroesophageal
junction were mobilized, and a gastrostomy (1 cm long) was
performed on the anterior wall of the stomach with subsequent
closure. The abdominal wall was closed using continuous sutures,
and the skin was closed intracutaneously. Carprofen (5 mg/kg
intraperitoneally [i.p.]) was administered for postoperative analge-
sia during surgery and on postoperative days 1 and 2 once a day.
2.3. Gene Expression Analysis and Tissue Preparation
On postoperative week 16, overnight-fasted animals were
treated with ketamine/xylazine (100 mg/kg and 10 mg/kg i.p.,
respectively) and were sacrificed by decapitation at the
beginning of the light phase. Fat pads weighing approximate-
ly 100 to 250 mg from four depots (inguinal, epididymal,
perirenal WAT, and interscapular BAT) were carefully dis-
sected and immediately frozen in liquid nitrogen and stored
at −80 °C for gene expression analysis. Inguinal (subcutane-
ous) and epididymal (visceral) WAT were selected as they are
well established depots that undergo browning [9]. Perirenal
(visceral) WAT was additionally selected on the basis of more
recent reports of browning [31,32]. RNA extraction and reverse
transcription were performed using the RNeasy Lipid Tissue
Mini Kit and the QuantiTect Reverse Transcription Kit (both
Qiagen, Hilden, Germany) following the manufacturer’s
instructions. Thermogenic regulatory genes highly expressed
in BAT and BeAT [33] selected for analysis included the
transcription factor PR domain containing 16 (PRDM16), which
is required for both BAT and BeAT thermogenic gene
induction [34], and cell death activator A (CIDEA), a mito-
chondrial protein first found to be enriched in BAT that
negatively regulates UCP1 function and thermogenesis [35].
BeAT-specific genes selected for analysis in this study
included the cell surface transmembrane protein 26
(TMEM26) and the nuclear receptor V-erbA-related protein 2
(Ear2) as they were found to be among the most highly
expressed in BeAT [34]. Fatty acid synthase (FASN) was used
as a positive control gene in WAT [36]. Gene expression was
analyzed by reverse transcription-quantitative PCR (RT-qPCR)
on the Light Cycler 480 platform using the SYBR Green
detection method following the manufacturer’s instructions
(Qiagen). Primers (Eurofins) were designed with reference to
Ensemble genome database and Primer3 software ensuring
that at least one primer spanned an exon–exon junction. The
sequences for primers used are listed in Table 1. For the reverse
transcriptase reaction, 1 μg RNA was reverse transcribed at 42C
for 25 minutes followed by a denaturation step at 95C for
3 minutes. For the qPCR, 100 ng of sample cDNA in duplicate
went through a pre-incubation stage at 95C for 15 minutes
followed by an annealing/amplification stage (45 cycles)
consisting of two steps; the first at 95C for five seconds and then
the second at 58C for 1 minute. A melting curve stage was also
added to the end to ensure purity of amplicons generated from
sample cDNA. CT valueswere then obtained and duplicates were
averaged. Expression levels of mRNA were analyzed by the ΔCT
methodwith normalization to beta actin. For intergroup compar-
isons, gene expression is presented relative to Sham controls.
2.4. Statistical Analysis
Results are expressed asmeans ± S.E.M. Two-wayANOVAwith
multiple comparisons was used to analyze differences in body
weight between the experimental groups. One-way ANOVA
with Bonferroni post-test comparison was used to analyze
differences in average daily food intake and in thermogenic and
BeAT gene expression in the adipose tissue depots between the
various experimental groups. Individual t-test was used to
analyze intra-tissue differences between BeAT-specific and
FASN gene expression in WAT and inter-tissue differences in
thermogenic gene expression betweenWAT and BAT.
3. Results
3.1. Body Eeight and Food Intake
Fig. 1A shows the postoperative body weight changes for all
three treatment groups. There was no difference in the
preoperative body weight between Sham (482 ± 7.5 g), RYGB
(477 ± 6.6 g) and BWM (462 ± 14.6 g) animals.
From postoperative week 2, body weights of RYGB and BWM
animals significantly diverged from Sham animals (428 ± 7.7 g,
431 ± 16.2 g and 494 ± 10.0 g respectively; P < 0.01 for Sham vs
RYGB animals, and P < 0.05 for Shamvs BWManimals). RYGB and
BWM groups continued to lose weight until postoperative week 3,
while Sham animals continued to gain weight until postoperative
week 9, after which body weights for all groups plateaued. On
postoperative week 16, the difference in body weight between
Table 1 – Primers used for RT-qPCR analysis.
Ear2 Forward: AGGCCATCGCGCTCTTC
Reverse: CAACATGGGCTGGGTCAGA
TMEM26 Forward: CTGGTCTCGGGAATCCTTGT
Reverse: TAGATCATCAGGACGAGGCG
UCP1 Forward: ATGACGTCCCCTGCCATTTA
Reverse: ATGACGTTCCAGGATCCGAG
PRDM16 Forward: CCACACAGAAGAGCGTGAGTACAA
Reverse: TGTGAACACCTTGACGCAGTTT
CIDEA Forward: TTCCTCGGCTGTCTCAATGT
Reverse: GCCCGCATAAACCAGGAAC
beta-Actin Forward: GGAGATTACTGCCCTGGCTCCTA
Reverse: GACTCA TCGTACTCCTGCTTGCTG
FASN Forward: CACAGCATT CAGTCCTATCCACAGA
Reverse: CACAGCCAACCAGATGCTTCA
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RYGB and BWMgroups versus the Shamgroupwas approximately
150 g (431 ± 8.1 g, 441 ± 16.8 g and 596 ± 9.5 g, respectively;
P < 0.0001 for Sham vs RYGB animals and P < 0.0001 for Sham vs
BWM animals).
Fig. 1B shows the average daily food intake for all three
experimental groups between postoperative weeks 8 to 16. Daily
food intakewas consistently lower in the RYGB compared to the
Sham group (22.52 ± 1.08 g versus 26.43 ± 0.59 g, respectively;
P < 0.01). BWM rats required significantly less food than RYGB
rats to maintain the same level of body weight (15.73 ± 0.83 g;
P < 0.0001 vs RYGB and vs BWM animals).
3.2. Thermoregulatory Gene Expression in BAT
To evaluate the possible differential influence of weight loss
following chronic caloric restriction and RYGB on changes in
BAT-mediated thermogenesis, thermoregulatory genes in BAT
were analyzed (Fig. 2). There was no change in uncoupling
protein 1 (UCP1) mRNA expression in BAT found in the RYGB-
operated study group compared to sham-operated ad libitum fed
controls (Fig. 2A). However, in the BWM group, the mRNA
expression of UCP1 in BAT was significantly lower compared to
Sham controls (P < 0.05) (Fig. 2A). The mRNA expression of
PRDM16 showed a similar pattern as UCP1 (Fig. 2B) with a clear
trend toward a reduction in BWM compared to Sham animals.
There were no changes in mRNA expression of CIDEA in BAT
between the Sham, RYGB, and BWM groups (Fig. 2C).
3.3. Beige Gene Expression in WAT
Having established the effects of RYGB on thermogenic gene
expression in BAT,wenext sought to assess thepossible beigeing of
various WAT depots after RYGB. Expression levels of mRNA of
BeAT-specific genes for all three treatment groups are illustrated in
Fig. 3. The expression level of TMEM26 was extremely low in
inguinal, epididymal, and perirenal WAT depots in all three
treatment groups compared to the positive control gene, ranging
froma 100 to 2000 times lower expression level (Table 2). Intergroup
comparison revealed no difference in TMEM26 expression level in
inguinal and epididymal fat depots (Fig. 3A and C). However in
perirenal fat, TMEM26 expression was significantly lower in RYGB
andBWManimalscomparedtoShamanimals (P < 0.05andP < 0.01
Fig. 1 – Body weights (A) and average daily food intakes (B) of sham-operated rats ad libitum fed (Sham), RYGB-operated rats
(RYGB), and sham-operated body weight matched rats (BWM). (A) Body weight was significantly higher in Sham rats (white
circles, n = 7) compared to RYGB rats (black circles, n = 10) and BWM rats (gray circles, n = 7) throughout the study as indicated
(gray box). Body weight of RYGB animals was not significantly different from body weight of BWM rats. (B) Average daily food
intake during postoperative weeks 8–16 for Sham rats (white column, n = 7), for RYGB rats (black column, n = 10), and for BWM
rats (gray column, n = 7). Data are shown as mean values ± S.E.M.
Fig. 2 – Thermoregulatory gene expression in BAT at a stage of body weight loss maintenance after RYGB. Interscapular BAT
was dissected at postoperative week 16 from sham-operated ad libitum fed (Sham, n = 7), RYGB-operated (RYGB, n = 10), and
sham-operated body weight matched (BWM, n = 7) rats and RT-qPCR analysis of mRNA expression of thermoregulatory genes
(UCP1, PRDM16, and CIDEA) was performed. Data are shown as mean values ± S.E.M.
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respectively) (Fig. 3E). Interestingly, FASN mRNA expression
level was significantly higher in inguinal WAT of the RYGB
group compared to both control groups (P < 0.001 for Sham rats
and P < 0.01 for BWM rats, Supplementary Fig. 1).
The expression level of Ear2 was higher in subcutaneous
and visceral WAT depots than TMEM26 in all three
treatment groups, but remained far lower compared to
the positive control gene (for details see Supplementary
Table 2). Intergroup comparisons revealed no differences in
Ear2 mRNA expression levels between the Sham, RYGB, and
BWM groups in inguinal, epididymal and perirenal WAT
depots (Fig. 3B, D, and F).
Fig. 3 – Beige adipose tissue-specific gene expression inWATat a stage of bodyweight lossmaintenance after RYGB. Subcutaneous
(SC), epididymal (EF) and perirenal (PF) WAT depots were dissected at postoperative week 16 from sham-operated ad libitum fed
(Sham, n = 7), RYGB-operated (RYGB, n = 10), and sham-operated bodyweightmatched (BWM, n = 7) rats and RT-qPCR analysis of
mRNA expression of genes selectively expressed in beige adipocytes (TMEM26 and Ear2) was performed. Data are shown asmean
values ± S.E.M. relative to sham-operated ad libitum fed group.
Table 2 – Fold higher mRNA expression and outcome of statistical analysis of positive control gene (FASN) compared to
beige adipocyte specific genes (TMEM26 and Ear2) in the different WAT depots for each treatment group.
Subcutaneous WAT Epididymal WAT Perirenal WAT
FASN vs TMEM26 (Sham-ad lib. fed) 153×: P < 0.05 103×: P < 0.05 97×: P < 0.05
FASN vs TMEM26 (RYGB) 596×: P < 0.0001 120×: P < 0.0001 1754×: P < 0.01
FASN vs TMEM26 (Sham-BWM fed) 124×: P < 0.0001 136×: P < 0.01 2063×: P < 0.05
FASN vs Ear2 (Sham-ad lib. fed) 9×: P < 0.01 6×: P < 0.01 19×: P < 0.05
FASN vs Ear2 (RYGB) 154×: P < 0.0001 6×: P < 0.0001 10×: P < 0.01
FASN vs Ear2 vs (Sham-BWM fed) 29×: P < 0.0001 7×: P < 0.001 69×: P < 0.05
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3.4. Thermoregulatory Gene Expression in WAT
To further verify the negative findings of BeAT-specific gene
expression in WAT depots after RYGB-induced weight loss,
we next analyzed the mRNA expression of thermoregulatory
genes in WAT depots. The expression level of CIDEA in
subcutaneous and visceral WAT depots was very low in all
three treatment groups when compared to its expression
level in BAT (for details see Table 3). As demonstrated in
Fig. 4A, C and E, no differences were found in CIDEA mRNA
expression levels between the Sham, RYGB, and BWM groups
in inguinal, epididymal, and perirenal WAT depots.
Fig. 4 – Thermoregulatory gene expression inWAT at a stage of body weight loss maintenance after RYGB. Subcutaneous (SC),
epididymal (EF) and perirenal (PR) WAT depots were dissected at postoperative week 16 from sham-operated ad libitum fed
(Sham, n = 7), RYGB-operated (RYGB,n = 10), and sham-operated bodyweightmatched (BWM,n = 7) rats andRT-qPCR analysis of
mRNA expression of thermoregulatory genes highly expressed in beige adipocytes (CIDEA and PRDM16)was performed. Data are
shown as mean values ± S.E.M. relative to sham-operated ad libitum fed group.
Table 3 – Fold higher mRNA expression in BAT and outcome of statistical analysis of thermoregulatory genes (CIDEA and
PRDM16) compared to the different WAT depots for each treatment group.
BAT vs Subcutaneous WAT BAT vs Epididymal WAT BAT vs Perirenal WAT
CIDEA (Sham-ad lib. fed) 101×: P < 0.01 83×: P < 0.01 50×: P < 0.01
CIDEA (RYGB) 30×: P < 0.001 27×: P < 0.001 34×: P < 0.001
CIDEA (Sham-BWM fed) 97×: P < 0.0001 64×: P < 0.0001 23×: P < 0.0001
PRDM16 (Sham-ad lib. fed) 6×: P < 0.05 6×: P < 0.05 22×: P < 0.05
PRDM16 (RYGB) 6×: P < 0.0001 12×: P < 0.0001 11×: P < 0.0001
PRDM16 (Sham-BWM fed) 2×: P < 0.05 3×: P < 0.05 11×: P < 0.05
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The mRNA expression level of PRDM16 in subcutaneous
and visceral WAT depots was slightly higher than that of
CIDEA, but was still significantly lower in all tissues analyzed
compared to its expression in BAT (Supplementary Table 3).
No differences were found in PRDM16 mRNA expression levels
between the sham-operated ad libitum fed, RYGB-operated,
and sham-operated BWM groups in inguinal, epididymal and
perirenal WAT depots (Fig. 4B, D, and F).
4. Discussion
Implementing a previously established rat model of RYGB, we
have reproduced animal andhuman findings that gastric bypass
surgery causes a pronounced reduction in body weight in obese
subjects which is maintained in the long term. [29,30,37,38]
Notably, the relative hypophagia after RYGB compared to Sham
rats only partially explains the reduction in body weight after
surgery, as the BWM counterparts required on average 30% less
food than the RYGB group tomaintain the same level of reduced
adiposity. Since malabsorption has previously been excluded in
this model [27] (and own unpublished data), an alternative
mechanism in addition to reduced calorie intake drives weight
loss maintenance after RYGB surgery.
Cumulating evidence from both human studies [23–25,39–41]
andanimalmodels [26–28,42] strongly support that gastric bypass
results in profound changes not only in eating behavior, but also
in energy expenditure. Indeed individuals who do not exhibit
increased energy expenditure after RYGB have been shown to
regain weight [43] suggesting that increased energy expenditure
after surgery is a critical mediator of sustained weight reduction.
Due to their thermogenic and energy expending potential, BAT
and BeAT are novel targets for anti-obesity treatments [8] and are
additionally thought to play an active role in clinical conditions of
negative energy balance [20,21]. We have previously shown in
rats that gastric bypass does not result in changes in BAT UCP1
expression ormetabolic activity compared to ad libitum fed sham-
operated controls [29]. The present study extends these observa-
tions and reveals that there is no difference in BeAT specific gene
expression in subcutaneous (inguinal) or visceral (epididymal and
perirenal) WAT depots at a stage of stabilized body weight
reduction after RYGBwhen compared to Sham and BWM control
animals. Therefore, increased facultative thermogenesis through
browning ofWAT depots unlikely contributes to the documented
increases in energy expenditure at a late stage after RYGB inmale
subjects. Of note, a recent study revealed browning of gonadal
WAT in female mice after RYGB associated with increased
natriuretic peptide signalling [44] indicative of sexual dimor-
phism with regards to the mechanisms of weight loss following
bariatric surgery.
We found a significant down-regulation in UCP1 mRNA
expression in BAT following caloric restriction-induced
weight loss compared to Sham animals, consistent with a
previous study [45], but not in animals following gastric
bypass-induced weight loss. Despite that the direct compar-
ison between both weight loss groups did not attain statistical
significance for UCP1 gene expression in BAT, these data
nevertheless suggest that under conditions of stabilized
weight reduction, gastric bypass partially prevents the ad-
justed decrease in BAT activity that promotes weight regain
following caloric restriction. The reasons for this are unclear
and require further mechanistic study. Interestingly, in
contrast to RYGB, energy expenditure, BAT thermogenic
gene expression and metabolic activity are decreased in rats
after biliopancreatic diversion, while after sleeve gastrectomy,
BAT thermogenic gene expression and metabolic activity
actually increase compared to sham operated ad libitum fed
and pair-fed controls [45]. These results suggest that different
metabolic surgical interventions may have diverse effects on
BAT mediated thermogenesis and energy expenditure.
We chose to control our RYGB group for body weight rather
than for feeding as the effect of sustainedweight reduction on
thermogenesis is the main interest of the present study. This
type of study design precluded an analysis of the effects of
gastric bypass on tissue specific modifications in gene
expression attributable to changes in feeding alone. Consid-
ering the marked differences in daily food intake between
RYGB and BWM groups mentioned above, future studies
implementing a pair-fed group may provide interesting
results concerning causes of changes in energy expenditure
and thermogenic gene expression in BAT and/or BeAT after
surgery. We surmise however that since pair-fed rats would
not lose as much weight as RYGB rats, energy expenditure
and/or UCP1 expression may not show a compensatory
reduction. This approach, if taken alone, could potentially
have obscured the findings we made in the present study.
The results from the present study are surprising in light of
the well documented increases in circulating GLP-1 and bile
acids after gastric bypass which both have been shown to
increase energy expenditure by recruitment of BAT and/or
BeAT [46,47]. Changes in energy expenditure after gastric
bypass surgery could be subserved by alternative signaling
molecules acting through highly metabolically active tissues
other than BAT and BeAT. For instance, the significant
rearrangement in gut structure after RYGB has been proposed
to contribute to increased energy expenditure [27,48]. Speci-
fically, the increased GLP-2 release after RYGB [49], which has
well-characterized cell proliferative effects on enterocytes,
particularly of the small intestine [50], may favor mucosal
growth [48], thus contributing to increased resting energy
expenditure and diet induced thermogenesis after surgery.
Significant mucosal hyperplasia has been documented post-
RYGB even at a stage of weight loss maintenance in rats,
associated with increased glucose uptake [49]. Another
metabolic candidate previously addressed in this context is
the melanocortin receptor-4 (MC4R). The MC4R is highly
expressed in the central and peripheral nervous systems
and its activation results in elevated energy expenditure [51].
The maintained weight loss and increased energy expendi-
ture in mice after RYGB is absent in mice lacking the MC4R in
sympathetic nervous system neurons [42]. While mecha-
nisms remain unclear, leptin has recently been shown to be
essential for weight loss maintenance after RYGB in mice [52].
Leptin-responsive hypothalamic POMC neurons, which syn-
thesize and release the MC4R agonist alpha-MSH, project to
the intermediolateral cell column [53] and may be engaged to
promote energy expenditure after surgery. Additionally, the
enhanced diet-induced thermogenesis after RYGB shown in
both rodent models [27,28] and in human studies [40,41] could
be due to increased activity of MC4R containing preganglionic
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sympathetic neurons [54], which synapse onto postganglionic
sympathetic neurons innervating skeletal muscle [55].
We found a significant up-regulation of FASN in RYGB rats
compared to both sham-operated groups specifically in subcu-
taneous fat, which is consistent with previous data [36]. Unlike
visceral WAT, where FASN expression is associated with
negative metabolic parameters, de novo lipogenesis and fat
accumulation in subcutaneous fat is thought to be protective
against obesity associated inflammation and to be beneficial to
metabolic health [56]. RYGBmay result in a favorable adipokine
profile (such as increased adiponectin [57]) leading to improved
glucose homeostasis through expansion of subcutaneousWAT.
There are several limitations to the present study. Firstly,
animals were housed under standardized temperatures below
thermoneutrality which may have impacted on BeAT/BAT-
mediated thermogenesis [58]. However, due to the similarly low
levels of BeAT genes found in all study groups, any induction of
BeAT in response to the lower than thermoneutrality conditions,
which could have masked changes after RYGB surgery, is very
unlikely. Secondly, we placed animals postoperatively on stan-
dard chow in order to prevent the development of fat taste
aversion [30] as well as to mimic the clinical situation where
patients actively avoid fatty foods after surgery. Although a diet
high in fat content might have facilitated thermogenic activity
[58], we do not think that diet choice represents a significant
confounder since a similar diet was used in a previous study
reporting increased energy expenditure in rodents after RYGB
surgery [27]. Thirdly, animals in our study were sacrificed in the
fasted and pharmacologically unstimulated state when BeAT
thermogenic function is low [59]. However, thiswould likely have
mainly effected expression ofUCP1 andnot of other thermogenic
or BeAT-specific genes. Indeed we found that UCP1 mRNA in
WAT depots were almost undetectable (data not shown).
Notably, CIDEAandPRDM16expression levels in theWATdepots
we analyzed have been shown to be unaffected by fasting [59].
Finally, the experiments in thepresent studywereperformedat a
late postoperative time point during stabilized weight reduction.
We selected this time point as differences in outcomes between
surgery and lifestyle interventions are most pronounced. Conse-
quently, the possible role ofWATbrowning/elevatedBATactivity
on altered energy expenditure at earlier time points after surgery
during active weight loss cannot be excluded by the present
study. In human studies increased energy expenditure after
surgery has been demonstrated as early as 6 weeks postopera-
tively [23], while other studies have shown increased energy
expenditure at 6 months after surgery, which still represents a
relatively early stage of active weight loss [24]. Thus, it would be
interesting to assess WAT browning at an early time point after
surgery in future studies, especially considering the remarkable
plasticity of BeAT and the potential reversibility of this effect [60].
The main strengths of the present study lie in the use of a
well-established rat model of RYGB allowing for detailed
analysis of surgery induced changes in BAT/BeAT gene
expression under highly standardized conditions, as well as
the inclusion of a BWM group which controlled for any
potential changes after surgery attributable to weight loss
alone. This experimental design led to novel observations
concerning BAT thermogenic function which could not have
been made in our previous study [29]. BeAT specific genes are
not always induced in WAT during browning [60]. By
additionally analyzing thermoregulatory gene expression in
WAT, our results were further substantiated as these genes
were found to be highly expressed in BAT as expected. The
high expression of FASN in subcutaneous WAT after RYGB is
not only consistent with previous findings [36], but also serves
to confirm the sensitivity of our methods of gene expression
detection implying that any induction of gene expression in
WAT after surgery would have been detected.
5. Conclusions
Taken together, the data from the present study suggest that
RYGB does not cause browning of WAT, but does prevent the
decreased BAT-mediated thermogenesis typically associated
withweight loss, whichmay contribute to anoverall increase in
energy expenditure and sustained weight reduction after RYGB
surgery. Considering the recent finding that RYGB does not
cause browning of subcutaneous abdominal WAT in humans
[33], BeAT could potentially still be exploited to improve weight
loss and/or treatment of obesity-related comorbidities in
patients with poor response to surgery.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.metabol.2015.06.010.
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The prevalence of obesity is rising in developed countries all over the world and has become 
one of the major challenges for their health care systems. 
Overweight has been shown to have manifold negative effects on several organ systems. It not 
only unfolds devastating consequences for the cardiovascular system, but also increases the 
risk of cancer, psychiatric disorders and musculoskeletal pathologies.  
The weight loss achieved through conservative treatment options can only rarely be sustained 
over a longer period of time. Compensatory counter regulation, for example in the form of a 
decrease in energy expenditure, has been described to undermine therapy success. In contrast, 
Roux-en-Y gastric bypass surgery (RYGB) produces a significant and above all sustained 
weight reduction. Previous studies have shown that this effect is not solely mediated by a 
reduction in energy intake but also by an increase in energy expenditure, that seems to be 
crucial for surgery’s success. In support of this, we and others observed that a body weigh t 
matched control group had to eat significantly less in order to reach the same weight loss 
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when compared to rats that underwent RYGB. In this work we were aiming to gain deeper 
insight into the mechanism behind RYGB’s effect on energy expenditure.  
In the last years, several findings demonstrated the presence of thermogenically active tissue 
in adults. Formerly thought to be of relevance only in infants, brown fat can be found in 
different depots in the full-grown human body. Furthermore it was reported that certain white 
fat cells have the potential to differentiate into cells equipped with enzymes capable of 
thermogenesis, the so called beige cells. Both brown and beige fat cells are expressing 
enzyme protein named uncoupling protein 1 (UCP1). UCP1 enables them to produce heat by 
short-circuiting the electron transport chain. In this process, substrates like glucose and lipids 
are metabolized which gives these tissues their weight lowering potential. Independently of 
weight reduction, a positive impact on glucose homeostasis and plasma lipid levels has been 
shown.  
After RYGB, an increase in body-thermogenesis has been observed, providing a possible 
explanation for RYGB’s effect on energy expenditure. We hypothesized that activation of 
brown adipose tissue and/or recruitment of beige adipose tissue within white fat depots may 
be responsible for this phenomenon.  
For investigation of this question, 24 male Wistar rats were fed a high-fat diet until they 
reached the target weight of 500g. Subsequently one group of ten received RYGB surgery 
whereas the remaining 14 animals underwent sham operation. After a recovery period, the 
sham-operated animals were further divided into one ad-libitum fed group and one body-
weight-matched group. The latter received only as much food as was necessary to achieve the 
same weight loss as the RYGB group. Body weight development and food intake were 
recorded for all three groups. On postoperative week 16, animals had reached a state of stable 
body weight and dissections were performed. Samples were collected from brown and white 
adipose tissue. After RNA extraction and reverse transcription, real-time quantitative polymer 
chain reaction was used to analyze the expression levels of relevant genes. Uncoupling 
protein 1 (UCP1), cell death activator A (CIDEA) and PR domain containing 16 (PRDM16) 
are thermoregulatory genes and served as markers for thermogenetic activity in brown and 
white fat. Furthermore the beige adipose tissue markers transmembrane protein 26 
(TMEM26) and V-erbA-related protein 2 (Ear2) were analyzed to assess potential „browning 
„of subcutaneous and visceral white fat depots. One-way-ANOVA, Two-way ANOVA and 
individual t-Tests were used for statistical analysis of differences in body weight, average 
daily food intake, and gene expression levels. 
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In accordance with previous studies, RYGB rats underwent a significant weight reduction. 
The body weight matched group had to eat 30% less in order to achieve the same weight loss. 
As malabsorption has previously been shown to not significantly contribute to this effect, 
these data underpinned the need to further investigate into alternative mechanisms of 
increased energy expenditure.  
Contrary to expectations, our analysis of subcutaneous and visceral white fat depots revealed 
no evidence for the recruitment of thermogenically active beige fat cells in white fat depots 
after RYGB. There was no difference between study groups in expression of beige fat markers 
or thermoregulatory genes.  
The analysis of thermoregulatory genes in brown adipose tissue revealed a significant down-
regulation of UCP1 after weight loss when comparing the body weight matched group to the 
sham-operated animals. A similar trend could be observed for PRDM16. This is consistent 
with the well-described compensatory decrease of energy expenditure after weight reduction. 
Although the direct comparison between the weight loss groups did not attain statistical 
significance, together these data suggest an attenuated decrease of brown adipose tissue 
activity after RYGB. This might contribute to the long-term sustainment of weight loss after 
surgery by preventing a decrease in energy expenditure.  
However there are limitations to our study. It was performed at a relatively late stage after 
weight loss. Given the high plasticity of white fat, the activity of brown and beige adipose 
tissue should be assessed at earlier postoperative stages.  
In accordance with our results, a subsequent study showed that RYGB-rats display reduced 
adaptive thermogenesis compared to ad-libitum fed rats and body weight matched rats when 
they are housed at room temperature. This was confirmed by a relative decrease in 
thermogenic capacity in RYGB rats, measured by UCP-1 expression and BAT-thermogenesis 
after stimulation (Abegg, Corteville, Bueter & Lutz, 2016). Another study performed in 
female mice showed mild browning of inguinal adipose tissue associated with increased 
natriuretic peptide and sympathetic signaling (Neinast et al., 2015). These findings highlight a 
potential gender difference of the effect of RYGB on beige adipose tissue thermogenesis.  
Together these findings reinforce the need to investigate alternative mechanisms causing the 
relative increase in energy expenditure after RYGB, such as surgery induced hyperplasia of 
enterocytes and changes in gut microbiota. 
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